His experience in building high-performing biotech organisations, advancing novel therapeutic platforms, and taking multiple therapies into the clinic makes him an invaluable addition to our mission.
At Icosphere, we are dedicated to transforming how scientists deliver DNA to cells for a range of disease conditions. Using our IcoGenesis Technology we can produce high-capacity vectors with unparalleled DNA carrying capabilities and improved infectivity, allowing lower doses and enhanced safety. Dr. Beadle’s strategic insight and deep operational expertise will play a pivotal role as we accelerate our growth and expand the impact of our technology across the life sciences.
Dr Ryan Cawood, CEO and Founder at Icosphere Biosciences said 'We are extremely pleased to be able to welcome John to our board of directors. As we look to commercialise our main manufacturing technology and develop our own clinical pipeline, his insight will be invaluable. The team and I are thrilled to have him on board for the next phase of our exciting journey.'